R Bagatell

Summary

Affiliation: The Children's Hospital of Philadelphia
Country: USA

Publications

  1. doi request reprint Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study
    Rochelle Bagatell
    Rochelle Bagatell, Lisa J States, and Alexandra Miller, Children s Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA Arlene Naranjo and Collin Van Ryn, University of Florida, Gainesville, FL Chaim Kirby and Sam L Volchenboum, University of Chicago, Chicago, IL Karen A Lyons, Yesenia Rojas, and Jed Nuchtern, Texas Children s Hospital and Baylor College of Medicine, Houston, TX Julie R Park, Seattle Children s Hospital and University of Washington, Seattle, WA Kieran McHugh and Penelope Brock, Great Ormond Street Hospital for Children, London, United Kingdom Thorsten Simon and Barbara Krug, University of Cologne Medical School, Cologne Dietrich von Schweinitz and Birgit Kammer, Dr von Hauner Children s Hospital and University of Munich, Munich, Germany Sabine Sarnacki, Hopital Necker Enfants Malades and Paris Descartes University Dominique Valteau Couanet, Institut Gustave Roussy, Universite Paris Sud, Paris, France and Claudio Granata and Luca Pio, Istituto Giannina Gaslini, Genoa, Italy
    J Clin Oncol 34:740-6. 2016
  2. pmc Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors
    R Bagatell
    Department of Pediatrics, The Children s Hospital of Philadelphia, Philadelphia, PA 19066, USA
    Clin Cancer Res 17:611-9. 2011
  3. pmc Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study
    Rochelle Bagatell
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    J Clin Oncol 29:208-13. 2011
  4. pmc Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database
    Rochelle Bagatell
    University of Arizona Health Sciences Center, Tucson, AZ, USA
    J Clin Oncol 27:365-70. 2009
  5. ncbi request reprint Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy
    Rochelle Bagatell
    University of Arizona, Department of Pediatrics and Steele Children s Research Center, Tuscon, AZ, USA
    J Clin Oncol 23:8819-27. 2005
  6. ncbi request reprint Neuroblastoma
    John M Maris
    Children s Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4318, USA
    Lancet 369:2106-20. 2007
  7. pmc A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors
    Elizabeth Fox
    The Children s Hospital of Philadelphia, Division of Oncology CTRB4016, 3501 Civic Center Blvd, Philadelphia, PA 19104, USA
    J Clin Oncol 28:5174-81. 2010
  8. doi request reprint Update on imaging and treatment of Ewing sarcoma family tumors: what the radiologist needs to know
    Winnie A Mar
    Department of Radiology, The University of Arizona College of Medicine, Tucson, AZ 85724 5067, USA
    J Comput Assist Tomogr 32:108-18. 2008
  9. ncbi request reprint Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin
    Rochelle Bagatell
    Steele Memorial Children s Research Center and The Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
    Int J Cancer 113:179-88. 2005
  10. ncbi request reprint Increased expression of the Hsp70 cochaperone HspBP1 in tumors
    Deborah A Raynes
    Department of Animal Sciences, University of Arizona, Tucson, AZ 85721, USA
    Tumour Biol 24:281-5. 2003

Collaborators

Detail Information

Publications11

  1. doi request reprint Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study
    Rochelle Bagatell
    Rochelle Bagatell, Lisa J States, and Alexandra Miller, Children s Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA Arlene Naranjo and Collin Van Ryn, University of Florida, Gainesville, FL Chaim Kirby and Sam L Volchenboum, University of Chicago, Chicago, IL Karen A Lyons, Yesenia Rojas, and Jed Nuchtern, Texas Children s Hospital and Baylor College of Medicine, Houston, TX Julie R Park, Seattle Children s Hospital and University of Washington, Seattle, WA Kieran McHugh and Penelope Brock, Great Ormond Street Hospital for Children, London, United Kingdom Thorsten Simon and Barbara Krug, University of Cologne Medical School, Cologne Dietrich von Schweinitz and Birgit Kammer, Dr von Hauner Children s Hospital and University of Munich, Munich, Germany Sabine Sarnacki, Hopital Necker Enfants Malades and Paris Descartes University Dominique Valteau Couanet, Institut Gustave Roussy, Universite Paris Sud, Paris, France and Claudio Granata and Luca Pio, Istituto Giannina Gaslini, Genoa, Italy
    J Clin Oncol 34:740-6. 2016
    ..This study was conducted to identify the preferred method of primary tumor response assessment for use in revised INRC...
  2. pmc Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors
    R Bagatell
    Department of Pediatrics, The Children s Hospital of Philadelphia, Philadelphia, PA 19066, USA
    Clin Cancer Res 17:611-9. 2011
    ....
  3. pmc Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study
    Rochelle Bagatell
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    J Clin Oncol 29:208-13. 2011
    ..This phase II study was conducted to determine the response rate associated with use of irinotecan and temozolomide for children with relapsed/refractory neuroblastoma...
  4. pmc Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database
    Rochelle Bagatell
    University of Arizona Health Sciences Center, Tucson, AZ, USA
    J Clin Oncol 27:365-70. 2009
    ..To evaluate the outcome of children with low-stage MYCN-amplified neuroblastoma and develop a rational treatment strategy, data from the International Neuroblastoma Risk Group (INRG) database were analyzed...
  5. ncbi request reprint Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy
    Rochelle Bagatell
    University of Arizona, Department of Pediatrics and Steele Children s Research Center, Tuscon, AZ, USA
    J Clin Oncol 23:8819-27. 2005
    ..The goal of Pediatric Oncology Group 9243 was to improve outcomes for children with intermediate-risk neuroblastoma (NB)...
  6. ncbi request reprint Neuroblastoma
    John M Maris
    Children s Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4318, USA
    Lancet 369:2106-20. 2007
    ..Finally, we discuss new approaches to treatment, including recently discovered molecular targets that might provide more effective treatment strategies with the potential for less toxicity...
  7. pmc A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors
    Elizabeth Fox
    The Children s Hospital of Philadelphia, Division of Oncology CTRB4016, 3501 Civic Center Blvd, Philadelphia, PA 19104, USA
    J Clin Oncol 28:5174-81. 2010
    ....
  8. doi request reprint Update on imaging and treatment of Ewing sarcoma family tumors: what the radiologist needs to know
    Winnie A Mar
    Department of Radiology, The University of Arizona College of Medicine, Tucson, AZ 85724 5067, USA
    J Comput Assist Tomogr 32:108-18. 2008
    ..This review article provides an update on multimodality imaging characteristics of Ewing sarcoma family tumors. Pathology of this tumor and current trends in medical and surgical treatment are briefly discussed...
  9. ncbi request reprint Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin
    Rochelle Bagatell
    Steele Memorial Children s Research Center and The Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
    Int J Cancer 113:179-88. 2005
    ..Our findings suggest that Hsp90 inhibitors may prove useful either alone or as a component of multi-drug regimens in the treatment of neuroblastoma and osteosarcoma...
  10. ncbi request reprint Increased expression of the Hsp70 cochaperone HspBP1 in tumors
    Deborah A Raynes
    Department of Animal Sciences, University of Arizona, Tucson, AZ 85721, USA
    Tumour Biol 24:281-5. 2003
    ..These studies have shown that HspBP1 is elevated in the tumors examined and therefore could be a new cancer marker...
  11. ncbi request reprint Two cases of pediatric neuroblastoma with tumor thrombus in the inferior vena cava
    Rochelle Bagatell
    Department of Pediatrics and Steele Memorial Children s Research Center, Tucson, Arizona, USA
    J Pediatr Hematol Oncol 24:397-400. 2002
    ..In one patient a pulmonary embolus developed after initiation of cytotoxic therapy; the second patient was prophylactically anticoagulated and had no embolic event...